THE INVESTOR

메뉴열기
December 16, 2018

SK Chemicals picks name for vaccine spin-off

PUBLISHED : April 12, 2018 - 14:15

UPDATED : April 12, 2018 - 18:37

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] SK Chemicals, the chemical and biopharmaceutical arm of SK Group, has picked a name for the vaccine unit it is planning to spin off this year, a company official said on April 12.

The unit, which will be focused on life sciences and eco-chemicals, submitted a patent application for the name “SK Bioscience,” to the Korean Intellectual Property Office last week.

“Nothing has been decided yet. It’s just one of the possible names,” an SK official told The Investor.


After completing the spin-off by end-2018, the new division will go public in three years, according to Ahn Jae-yong, head of SK Chemicals’ vaccine division.

In a recent interview with the press, Ahn stressed that making inroads into global markets will be one of the key missions of his firm. “We have a three-phase strategy starting with the local market, then targeting emerging markets and finally moving onto the US and Europe with our global partners,” he said.

The spin-off comes as SK Group is seeking to improve its biotechnology units by establishing independent entities for them. In 2015, SK Chemicals spun off its plasma-derivatives developer to set up SK Plasma. For over a decade, SK Chemicals has been centered on developing vaccines. The firm invested 400 billion won (US$374 million) into related research and manufacturing sites.

By Park Han-na (hnpark@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.